title: Mecamylamine effects on haloperidol-induced catalepsy and defecation.
abstract: Recent clinical experience with Tourette syndrome (TS) patients suggests that the nicotinic receptor antagonist, mecamylamine (Inversine), may be a useful adjunct to neuroleptic therapy for controlling tic symptom. This is consistent with previous preclinical findings demonstrating that mecamylamine can potentiate the cataleptic effects of neuroleptics in rats. However, these earlier preclinical studies employed high doses (1-2.5 mg/kg) of mecamylamine that may not be clinically relevant since human doses of mecamylamine used to treat TS have been much lower (0.03-0.1 mg/kg). In order to test the potential therapeutic properties of mecamylamine preclinically, we conducted catalepsy experiments in rats employing both a low and high dose of mecamylamine in combination with haloperidol. Sixty-four male Sprague Dawley rats were randomized into four treatment groups (n = 16/group). Each rat received an injection of either saline or mecamylamine (0.1 or 3.0 mg/kg s.c.) followed one hour later with a second injection of either saline or haloperidol (0.4 mg/kg s.c.). The bar test was used to measure duration of catalepsy at 3 hrs following the second injection. The results demonstrated that only the mecamylamine treated rats showed statistically significant haloperidol-induced catalepsy when measured at 3 hrs. In addition, haloperidol-induced defecation was not affected by the 0.1 mg/kg mecamylamine dose, but completely abolished by the 3.0 mg/kg dose. These findings suggest that a clinically relevant dose of mecamylamine (0.1 mg/kg) can affect the duration of haloperidol-induced catalepsy without having significant effects on gastrointestinal function.
authors.affiliation: Center for Aging and Brain Repair, Department of Psychology, Pharmacology, University of South Florida, College of Medicine Tampa, Florida 33612, USA.
authors.forename: P R
authors.initials: PR
authors.lastname: Sanberg
authors.forename: M B
authors.initials: MB
authors.lastname: Newman
authors.forename: J J
authors.initials: JJ
authors.lastname: Manresa
authors.forename: S E
authors.initials: SE
authors.lastname: Potts
authors.forename: F
authors.initials: F
authors.lastname: Alvarez
authors.forename: D W
authors.initials: DW
authors.lastname: Cahill
authors.forename: R D
authors.initials: RD
authors.lastname: Shytle
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000378:metabolism*; D002375:Catalepsy / Q000139:chemically induced*; D003672:Defecation / Q000187:drug effects*; D004357:Drug Synergism; D006220:Haloperidol / Q000009:adverse effects* / Q000378:metabolism*; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D014150:Antipsychotic Agents; D018733:Nicotinic Antagonists; D008464:Mecamylamine; D006220:Haloperidol